A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimo… (NCT07561814) | Clinical Trial Compass
RecruitingNot Applicable
A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
China1,030 participantsStarted 2025-12-08
Plain-language summary
The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.
The main questions it aims to answer are:
* Can combining these types of data more accurately estimate how long a person might survive?
* Can it better predict the risk of the cancer coming back?
Participants will not have any extra tests or treatments. They will:
* Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)
* Receive a follow-up phone call about every 3 months for up to 3 years to share health updates
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years.
* Histologically or cytologically confirmed diagnosis of pancreatic cancer.
* Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.
* Underwent surgical treatment for pancreatic cancer at a participating center of this study.
Exclusion Criteria:
* Age \< 18 years (minors).
* Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;
* patients unable to comply with follow-up or provide informed consent.
* Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.